JP2024545420A5 - - Google Patents

Info

Publication number
JP2024545420A5
JP2024545420A5 JP2024532444A JP2024532444A JP2024545420A5 JP 2024545420 A5 JP2024545420 A5 JP 2024545420A5 JP 2024532444 A JP2024532444 A JP 2024532444A JP 2024532444 A JP2024532444 A JP 2024532444A JP 2024545420 A5 JP2024545420 A5 JP 2024545420A5
Authority
JP
Japan
Prior art keywords
deletion
amino acid
cov
glycoprotein
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024532444A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024545420A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/080700 external-priority patent/WO2023102448A2/en
Publication of JP2024545420A publication Critical patent/JP2024545420A/ja
Publication of JP2024545420A5 publication Critical patent/JP2024545420A5/ja
Pending legal-status Critical Current

Links

JP2024532444A 2021-11-30 2022-11-30 コロナウイルスワクチン製剤 Pending JP2024545420A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202163284497P 2021-11-30 2021-11-30
US63/284,497 2021-11-30
US202163292120P 2021-12-21 2021-12-21
US63/292,120 2021-12-21
US202163293519P 2021-12-23 2021-12-23
US63/293,519 2021-12-23
US202263332530P 2022-04-19 2022-04-19
US63/332,530 2022-04-19
US202263367678P 2022-07-05 2022-07-05
US63/367,678 2022-07-05
PCT/US2022/080700 WO2023102448A2 (en) 2021-11-30 2022-11-30 Coronavirus vaccine formulations

Publications (2)

Publication Number Publication Date
JP2024545420A JP2024545420A (ja) 2024-12-06
JP2024545420A5 true JP2024545420A5 (cg-RX-API-DMAC7.html) 2025-11-13

Family

ID=86613115

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024532444A Pending JP2024545420A (ja) 2021-11-30 2022-11-30 コロナウイルスワクチン製剤

Country Status (10)

Country Link
US (1) US20250025549A1 (cg-RX-API-DMAC7.html)
EP (1) EP4440613A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024545420A (cg-RX-API-DMAC7.html)
KR (1) KR20240125935A (cg-RX-API-DMAC7.html)
AU (1) AU2022399829A1 (cg-RX-API-DMAC7.html)
CA (1) CA3241118A1 (cg-RX-API-DMAC7.html)
IL (1) IL313254A (cg-RX-API-DMAC7.html)
MX (1) MX2024006589A (cg-RX-API-DMAC7.html)
TW (1) TW202332685A (cg-RX-API-DMAC7.html)
WO (1) WO2023102448A2 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
CN116622651A (zh) * 2022-03-25 2023-08-22 中国农业科学院哈尔滨兽医研究所(中国动物卫生与流行病学中心哈尔滨分中心) 缺失Furin酶切位点的新冠病毒株及其应用
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
WO2024089638A1 (en) * 2022-10-28 2024-05-02 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine
US20250144200A1 (en) 2023-11-06 2025-05-08 Novavax, Inc. Intranasal immunogenic compositions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021214064A1 (en) * 2020-01-27 2022-08-18 Novavax, Inc. Coronavirus vaccine formulations
WO2021154763A1 (en) * 2020-01-28 2021-08-05 Modernatx, Inc. Coronavirus rna vaccines
TW202204380A (zh) * 2020-01-31 2022-02-01 美商詹森藥物公司 用於預防及治療冠狀病毒感染之組合物及方法-sars-cov-2疫苗
JP2025500433A (ja) * 2021-12-23 2025-01-09 ノババックス,インコーポレイテッド 抗SARS-CoV-2スパイク(S)抗体およびCOVID-19の処置におけるそれらの使用
IL318555A (en) * 2022-07-26 2025-03-01 Novavax Inc ACE2 Blockade Test to Assess the Immunogenicity of Vaccines
US20260028644A1 (en) * 2022-07-26 2026-01-29 Novavax, Inc. Pseudovirus based neutralization assay for evaluating vaccine immunogenicity

Similar Documents

Publication Publication Date Title
US9951113B2 (en) Lectin compositions and methods for modulating an immune response to an antigen
JP2026026092A5 (cg-RX-API-DMAC7.html)
JP2023512648A5 (cg-RX-API-DMAC7.html)
JP2010500399A5 (cg-RX-API-DMAC7.html)
CN116655748B (zh) 一种截短型水痘-带状疱疹病毒gE蛋白及其应用
JP2024511412A5 (cg-RX-API-DMAC7.html)
JP2024516309A5 (cg-RX-API-DMAC7.html)
CA2496384C (en) Lectin compositions and methods for modulating an immune response to an antigen
US7629440B2 (en) Lectin compositions and methods for modulating an immune response to an antigen
US20080063649A1 (en) Methods of priming the immunogenic activity of vaccines useful for eliciting a protective immune response
RU2018111760A (ru) Вакцинные композиции, характеризующиеся улучшенной стабильностью и иммуногенностью
JP6676661B2 (ja) ブタ生殖器呼吸器症候群及びブタサーコウイルス関連疾患に対するワクチン組成物
WO2019092002A1 (en) Pharmaceutical compositions for treatment or prevention of viral infections
Chiou et al. Effect of cecropin B and a synthetic analogue on propagation of fish viruses in vitro
CN113226364A (zh) 组合物和方法
JP2023542297A5 (cg-RX-API-DMAC7.html)
JP2024523329A5 (cg-RX-API-DMAC7.html)
JP4797149B2 (ja) インフルエンザウイルスに対するベクターワクチン
Wang et al. Embryonic stem cells attenuate viral myocarditis in murine model
JPWO2016059911A1 (ja) マラリアワクチン
KR20120129893A (ko) 고령자에 보호 면역을 제공하기 위한 방법 및 조성물
CA2183260A1 (en) Prolactin as a vaccine adjuvant
JP2024511356A5 (cg-RX-API-DMAC7.html)
JP2024539520A5 (cg-RX-API-DMAC7.html)
CN116390751A (zh) 多价β-冠状病毒疫苗、其设计和用途